12:00 AM
 | 
Apr 15, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Temodal temozolomide regulatory update

EMA's CHMP recommended suspending marketing authorizations for 7 generics from Teva after concluding that studies conducted at a Houston lab owned by CRO PRACS Institute (Fargo, N.D.) were not reliable in supporting the drugs approval. The agency said that...

Read the full 171 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >